Compare Moderna, Inc. (MRNA) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Royal Caribbean Cruises Ltd — how do they compare? Moderna, Inc. trades at $215.16 (market cap $78.65B), while Royal Caribbean Cruises Ltd trades at $280.49 (market cap $75.26B). The key difference: Moderna, Inc. and Royal Caribbean Cruises Ltd are close in size by market cap, and Royal Caribbean Cruises Ltd pays a 2.13% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Royal Caribbean Cruises Ltd for 85 Days on average.
| MRNA | RCL | |
|---|---|---|
Market Cap | $78.65B | $75.26B |
Volume | 37,373,437 | 1,958,628 |
Sector | Health | Consumer Cyclical |
52-Week High | $203.46 | $348.03 |
52-Week Low | $22.36 | $230.30 |
Typical Hold Time | 59 Days | 85 Days |
Enterprise Value | $74.80B | $97.91B |
Dividend Yield | — | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Royal Caribbean (RCL) trades at $282.36, down 2.25% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamental performance with Q1 and Q2 2026 earnings beats, revenue growth to $17.93B in 2025, and improving profit margins. Recent developments include a $3B investment in Sandals Resorts, expanding into the all-inclusive resort market. Analyst consensus remains positive with a $346.67 price target and 51% buy ratings.
RCL presents a compelling growth story with strong earnings momentum and strategic expansion, though investors face risks from high leverage, fuel cost volatility, and execution challenges from the Sandals acquisition. The stock's current valuation appears reasonable given growth prospects, but requires monitoring of debt levels and integration success.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
